May 8, 2025 The Dermatology Digest: April/May Supplement: Integrating Gene Expression Profile Testing for Melanoma: Weighing the Options
May 5, 2025 GenomeWeb: Castle Biosciences to Expand GI Offerings With Previse Merger, Discontinue Mental Health PGx Test
May 2, 2025 Dermatology Times: DecisionDx-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients Unlikely to Benefit from Sentinel Lymph Node Biopsy
May 1, 2025 The Clinical Trial Vanguard: DecisionDx®-Melanoma Test Outperforms in Low-Risk SLN Positivity
May 1, 2025 The Dermatology Digest: Castle’s DecisionDx-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of SLN Positivity
Apr 18, 2025 Dermatology Times: Gene Expression Profile Testing Offers Clinicians a Path to Safely Avoid SLNB in Low-Risk Melanoma Patients
Apr 11, 2025 Targeted Oncology: Gene Expression Test Accurately Predicts Low SLN Positivity Risk in Melanoma
